Pancreatic Cancer Research

ResearcherJiangsu UniversityActive in the last 2 years

Shu Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4571-742X; OpenAlex author ID A5059125543. Sources: OpenAlex.

Their work

Papers
16 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 3 papers · 2026: 1 paper

Papers 16

  1. Sotorasib combined with 3-methyladenine for the treatment of KRAS G12C-mutant pancreatic cancer and its underlying mechanisms. Co-author DOI 10.1016/j.tranon.2026.102821↗
  2. Epigenetic suppression of Nrf2-Slc40a1 axis induces ferroptosis and enhances immunotherapy in pancreatic cancer. Last author DOI 10.1136/jitc-2025-013269↗
  3. Targeting sphingosine-1-phosphate receptor 1 alleviates neuropathic pain associated with pancreatic ductal adenocarcinoma in mice and inhibits tumor progressio… Co-author DOI 10.1177/17448069251371549↗
  4. Mitochondrial-targeted photodynamic therapy combined with TGF-β inhibition potentiates anti-PD-1 therapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12951-025-03795-z↗
  5. CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202305279↗
  6. HHLA2 deficiency inhibits pancreatic cancer progression and THP-1 macrophage M2 polarization via EGFR/MAPK/ERK and mTOR/AKT pathway. Co-author DOI 10.1186/s12957-024-03409-2↗
  7. Protein tyrosine phosphatase nonreceptor type 2 exerts antimetastatic functions in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mc.23554↗
  8. Lithium chloride induces apoptosis by activating endoplasmic reticulum stress in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2023.101792↗
  9. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-023-40727-7↗
  10. Hesperadin suppresses pancreatic cancer through ATF4/GADD45A axis at nanomolar concentrations. Last author DOI 10.1038/s41388-022-02328-4↗
  11. Pirfenidone-loaded exosomes derived from pancreatic ductal adenocarcinoma cells alleviate fibrosis of premetastatic niches to inhibit liver metastasis. Co-author DOI 10.1039/d2bm00770c↗
  12. Analysis of T-cell receptor repertoire in peripheral blood of patients with pancreatic cancer and other pancreatic diseases. Co-author DOI 10.1111/jcmm.16358↗
  13. Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent man… Co-author DOI 10.1186/s13148-021-01016-6↗
  14. PPARγ/SOD2 Protects Against Mitochondrial ROS-Dependent Apoptosis via Inhibiting ATG4D-Mediated Mitophagy to Promote Pancreatic Cancer Proliferation. Co-author DOI 10.3389/fcell.2021.745554↗
  15. Plasma-Derived Exosomal ALIX as a Novel Biomarker for Diagnosis and Classification of Pancreatic Cancer. Last author DOI 10.3389/fonc.2021.628346↗
  16. ALDH1A3 Accelerates Pancreatic Cancer Metastasis by Promoting Glucose Metabolism. Co-author DOI 10.3389/fonc.2020.00915↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaoping Zou · 11 shared papers, 2020–2024 · strength 1.54
  2. Ying Lv · 10 shared papers, 2021–2026 · strength 1.49
  3. Shanshan Shen · 8 shared papers, 2020–2023 · strength 1.02
  4. Yixuan Zhang · 4 shared papers, 2023–2025 · strength 0.76
  5. Yixuan Zhang · 5 shared papers, 2021–2023 · strength 0.66
  6. Ying Lv · 4 shared papers, 2020–2025 · strength 0.60
  7. Shijin Xu · 3 shared papers, 2024–2025 · strength 0.58
  8. Siqi Zhou · 3 shared papers, 2021–2024 · strength 0.48
  9. Hao Wu · 3 shared papers, 2022–2023 · strength 0.42
  10. Hui Wang · 3 shared papers, 2021–2023 · strength 0.38
  11. Lei Wang · 3 shared papers, 2020–2023 · strength 0.34
  12. Lei Wang · 2 shared papers, 2022–2025 · strength 0.32
  13. Xuetian Qian · 3 shared papers, 2020–2021 · strength 0.31
  14. Hongzhen Li · 3 shared papers, 2020–2021 · strength 0.31
  15. Shuang Nie · 3 shared papers, 2020–2021 · strength 0.31
  16. Bo Kong · 3 shared papers, 2020–2021 · strength 0.31
  17. Xiaoping Zou · 2 shared papers, 2021–2025 · strength 0.31
  18. Yixuan Zhang · 2 shared papers, 2022–2024 · strength 0.31
  19. Yukun Li · 1 shared paper, 2026 · strength 0.27
  20. Chao Yan · 2 shared papers, 2022–2023 · strength 0.26
  21. Dongming Zhu · 2 shared papers, 2021–2023 · strength 0.25
  22. Shenquan Cai · 1 shared paper, 2025 · strength 0.22
  23. Gao-jian Tao · 1 shared paper, 2025 · strength 0.22
  24. Jiajun Zhang · 1 shared paper, 2025 · strength 0.21
  25. Ziwei Zhang · 1 shared paper, 2025 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.